Related Experiment Video
Updated: May 9, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
First-in-class angiotensin receptor neprilysin inhibitor in heart failure
O Vardeny1, T Tacheny, S D Solomon
1School of Pharmacy, University of Wisconsin, Madison, Wisconsin, USA.
Abstract:
Neprilysin inhibitors augment the natriuretic peptide system by preventing the breakdown of atrial natriuretic peptide and B-type natriuretic peptide. LCZ696, an angiotensin receptor neprilysin inhibitor composed of a neprilysin inhibitor prodrug and the angiotensin receptor antagonist valsartan, has proven effective in hypertension, has shown promise in a pilot trial of heart failure with preserved ejection fraction, and is being tested in a large outcomes trial of heart failure with reduced ejection fraction. A preserved ejection fraction outcomes trial is beginning.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Heart Failure V: Medical Management
Antihypertensive Drugs: Direct Renin Inhibitors
Heart Failure Drugs: β-Blockers
Heart Failure Drugs: Inotropic Agents
